等待开盘 04-01 09:30:00 美东时间
-0.660
-1.44%
今日重点评级关注:Maxim Group:上调Theriva Biologics评级至"买入",目标价1美元;HC Wainwright & Co.:维持Bicara Therapeutics"买入"评级,目标价从40美元升至42美元
今天 16:34
今日重点评级关注:HC Wainwright & Co.:维持OCUGEN"买入"评级,目标价从7美元升至10美元;HC Wainwright & Co.:维持Maze Therapeutics"买入"评级,目标价从60美元升至110美元
03-26 11:41
Raymond James analyst Justin Jenkins maintains Delek US Holdings (NYSE:DK) with a Outperform and raises the price target from $47 to $54.
03-26 01:16
今日重点评级关注:韦德布什:维持Black Diamond Therapeutic"跑赢大市"评级,目标价从13美元升至14美元;花旗:维持Olema Pharmaceuticals"买入"评级,目标价从60美元升至62美元
03-18 10:48
Mizuho analyst Nitin Kumar maintains Delek US Holdings (NYSE:DK) with a Outperform and raises the price target from $51 to $54.
03-18 01:49
Delek US EVP Joseph Israel Disposes of Common Shares Joseph Israel, EVP of Delek US Holdings Inc., reported a disposal of the company’s common shares. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artifi
03-07 10:18
Delek US EVP Special Projects Reuven Spiegel Disposes of 20,000 Common Shares Reuven Spiegel, EVP, Special Projects at Delek US Holdings Inc., reported a disposal of the company’s common shares. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public
03-07 10:17
Delek US Director William J Finnerty Disposes of Common Shares William J. Finnerty, a director of Delek US Holdings Inc., reported a disposal of the company’s common shares. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT)
03-07 10:17
Delek US (($DK)) has held its Q4 earnings call. Read on for the main highlights...
03-03 08:21
华盛资讯2月28日讯,Delek Us控股公布2025财年年度业绩,公司年度营收107.23亿美元,同比下降9.5%,归母净利润亏损0.23亿美元,同比亏损缩窄95.9%。
02-28 02:18